Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
100%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

completed150%
withdrawn150%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_1

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
withdrawnphase_1

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

NCT03277755

Clinical Trials (2)

Showing 2 of 2 trials
NCT03155893Phase 1

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

Completed
NCT03277755Phase 1

A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function

Withdrawn

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2